Literature DB >> 19557078

TET2 mutations in myelodysplasia and myeloid malignancies.

Charles G Mullighan1.   

Abstract

The genetic basis of myelodysplasia has long been enigmatic, with few common targets of mutation known. A new study reports common mutations in the TET2 gene in myelodysplasia and related myeloid malignancies, suggesting that TET2 has an important role in hematopoiesis and in the pathogenesis of this disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19557078     DOI： 10.1038/ng0709-766

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  10 in total

Review 1.  Genetics of therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  J Pedersen-Bjergaard; M K Andersen; M T Andersen; D H Christiansen
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

2.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

3.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

4.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

5.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

6.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

7.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

Review 8.  Myelodysplastic syndromes.

Authors:  Stephen D Nimer
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

9.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Salil Goorha; Ina Radtke; Christopher B Miller; Elaine Coustan-Smith; James D Dalton; Kevin Girtman; Susan Mathew; Jing Ma; Stanley B Pounds; Xiaoping Su; Ching-Hon Pui; Mary V Relling; William E Evans; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

10.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Authors:  Benjamin L Ebert; Jennifer Pretz; Jocelyn Bosco; Cindy Y Chang; Pablo Tamayo; Naomi Galili; Azra Raza; David E Root; Eyal Attar; Steven R Ellis; Todd R Golub
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962
  10 in total
  23 in total

1.  Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells.

Authors:  Hao Wu; Yi Zhang
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

2.  Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.

Authors:  Johanna Flach; Frank Dicker; Susanne Schnittger; Alexander Kohlmann; Torsten Haferlach; Claudia Haferlach
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

3.  Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

Authors:  Elodie Pronier; Carole Almire; Hayat Mokrani; Aparna Vasanthakumar; Audrey Simon; Barbara da Costa Reis Monte Mor; Aline Massé; Jean-Pierre Le Couédic; Frédéric Pendino; Bruno Carbonne; Jérôme Larghero; Jean-Luc Ravanat; Nicole Casadevall; Olivier A Bernard; Nathalie Droin; Eric Solary; Lucy A Godley; William Vainchenker; Isabelle Plo; François Delhommeau
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

4.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.

Authors:  H Yang; Y Liu; F Bai; J-Y Zhang; S-H Ma; J Liu; Z-D Xu; H-G Zhu; Z-Q Ling; D Ye; K-L Guan; Y Xiong
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

Review 5.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elli Papaemmanuil; David T Bowen; Jacqueline Boultwood; Matteo G Della Porta; Cristiana Pascutto; Erica Travaglino; Michael J Groves; Anna L Godfrey; Ilaria Ambaglio; Anna Gallì; Matteo C Da Vià; Simona Conte; Sudhir Tauro; Norene Keenan; Ann Hyslop; Jonathan Hinton; Laura J Mudie; James S Wainscoat; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Eva Hellström-Lindberg; Mario Cazzola
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

7.  Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.

Authors:  Wei Zhang; Zonghong Shao; Rong Fu; Huaquan Wang; Lijuan Li; Hui Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing.

Authors:  Yun Huang; William A Pastor; Yinghua Shen; Mamta Tahiliani; David R Liu; Anjana Rao
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

Review 9.  Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?

Authors:  Gabriella Ficz; John G Gribben
Journal:  Genomics       Date:  2014-08-30       Impact factor: 5.736

10.  SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

Authors:  Manja Meggendorfer; Andreas Roller; Torsten Haferlach; Christiane Eder; Frank Dicker; Vera Grossmann; Alexander Kohlmann; Tamara Alpermann; Kenichi Yoshida; Seishi Ogawa; H Phillip Koeffler; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.